Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Notice anything different about #11

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Notice anything different about #11

tada

Oct 26, 2023 12:13AM

Re: Notice anything different about #11

rocketman2

Oct 26, 2023 11:36AM

Re: Notice anything different about #11

fouremm

Oct 26, 2023 01:23PM

Re: Notice anything different about #11

tada

Oct 26, 2023 08:14PM

Re: Notice anything different about #11

jbuffett62

Oct 26, 2023 10:10PM

Re: Notice anything different about #11

fouremm

Oct 27, 2023 12:09AM

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Notice anything different about #11

in response to

Re: Notice anything different about #11

fouremm

posted on Oct 27, 2023 09:03AM

Isn't the takeaway from this Clinical Trial, that ZEN-3694 is not in combination with another BP drug, and with any success, ZEN-3694 remains solely in the hands and control of Zenith, to benefit its shareholders? In all the other 12 clinical trials, ZEN-3694 is in combination with BP drugs.